Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOXO1 | Q12778 | 1/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14192845 | 1.00 | FOXO1 (0.56) | FOXO1ROCK2NPC1RAB9ACHEK1 | |
| SCHEMBL13490688 | 0.96 | FOXO1 (0.51) | FOXO1ROCK2NPC1RAB9ACHEK1 | |
| SCHEMBL3199404 | 0.90 | RAB9A (0.51) | FOXO1NPC1RAB9ACHEK1 | |
| Trifluoroacetic Acid SCHEMBL3211487 | 0.90 | FOXO1 (0.46) | FOXO1ROCK2CHEK1HTR2BHDAC3 | |
| SCHEMBL3206398 | 0.89 | RAB9A (0.54) | NPC1RAB9ACHEK1 | |
| SCHEMBL13490408 | 0.89 | RAB9A (0.54) | NPC1RAB9ACHEK1 | |
| SCHEMBL3219584 | 0.89 | RAB9A (0.54) | NPC1RAB9ACHEK1 | |
| SCHEMBL3223163 | 0.89 | RAB9A (0.54) | NPC1RAB9ACHEK1 | |
| Hydrochloric Acid SCHEMBL3206504 | 0.89 | RAB9A (0.53) | NPC1RAB9ACHEK1 | |
| Hydrochloric Acid SCHEMBL3213336 | 0.89 | RAB9A (0.53) | NPC1RAB9ACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | ACIN1, HAT1, CCNE1 | FOXO1 2257/4885ROCK2 2025/4885NPC1 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.